Cooperative Agreement U01CA305709
Award Date 8/7/25
Completion Date 7/31/29
Dollars Obligated $4.9M
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
California, USA
Similar Awards
- The federal Cooperative Agreement award, totaling $4,234,248 and provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), aims to comprehensively characterize the T-cell response to Kaposi Sarcoma Herpesvirus (KSHV) to enable specific immune therapy. The award, with a performance period from September 2025 to August 2029, is granted to the Fred Hutchinson Cancer Center (also known as Seattle Cancer Care Alliance) to conduct research that could lead to strategies to...
- This Project Grant award of $188,169 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of California, Davis (UC Davis) supports the development of a gene therapy vector using the adeno-associated virus (AAV) system to target Kaposi's sarcoma-associated herpesvirus (KSHV)-associated malignancies. The goal is to selectively express therapeutic genes, such as the thymidine kinase (TK)/ganciclovir (GCV) system, in KSHV-infected tumor cells that express...
- This federal Project Grant award, with ID R01CA290700, was provided by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396). The $564,698 award to the University of California, Davis (UC Davis) will fund a 5-year research project to investigate the role of the terminal repeat sequence in regulating the Kaposi's sarcoma-associated herpesvirus (KSHV) lytic gene promoters. The research aims to better understand the KSHV gene regulation mechanisms, with the...
- This federal Project Grant award of $216,013, provided by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research), supports research aimed at investigating the effects of caspases and antiviral responses on Kaposi's sarcoma-associated herpesvirus (KSHV) tumorigenesis. The research, conducted by the University of Wisconsin-Madison, utilizes a 3D primary human endothelial cell organoid model to better understand how activation of the interferon (IFN) pathway, either through direct...
- This $877,104 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research CFDA program, supports research to investigate the molecular mechanisms of Kaposi's sarcoma-associated herpesvirus (KSHV) infection and persistence. The research aims to delve deeper into how KSHV infection impacts immune cells, such as monocytes/macrophages and B cells, and how viral latency is established in B cells. Key aspects of the...
- This federal Project Grant award of $185,513, provided by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research), aims to develop O'PROTAC-based degraders that specifically target the KSHV-encoded LANA oncoprotein to interfere with the survival of Kaposi's sarcoma-associated herpesvirus (KSHV)-positive tumor cells. The award, with a project period from Nov 2024 to Oct 2026, is funding research at the University of Arkansas for Medical...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) provides $402,150 to the University of Florida to investigate the viral mechanism by which the Kaposi's sarcoma-associated herpesvirus (KSHV) regulates host transcription factors to promote its own lytic reactivation cycle. The key aims are to dissect the mechanism of interaction between KSHV viral proteins and the host forkhead-associated (FHA) domain...
- This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) provides $411,400 to Northwestern University to develop and characterize a cell culture model of Kaposi's sarcoma (KS). The primary objective is to identify KSHV-induced cellular genes that promote the loss of contact inhibition of proliferation (CIP) in KSHV-infected lymphatic endothelial cells (KLECs), which are believed to be the cell of origin for KS tumors. The...
- The National Cancer Institute (CFDA 93.396 Cancer Biology Research) awarded a $1,349,322 Project Grant to the University of Pittsburgh to study how the Kaposi's sarcoma-associated herpesvirus (KSHV) manipulates cellular metabolic pathways, specifically the methionine/S-adenosylmethionine (SAM) cycle, to maximize viral latent and lytic infections. The project aims to identify KSHV-regulated methyltransferase METTL16-specific N6-methyladenosine (m6A) marks, delineate the mechanisms by which the...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $430,285 Project Grant to Towson University to investigate RTA-induced ubiquitination in Kaposi's Sarcoma Herpesvirus (KSHV) for the period of February 1, 2025 to January 31, 2028. The project aims to identify cellular targets for intervention by studying novel virus-host interactions involving the cellular ubiquitin-proteasome...